A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer

Brief summary public domain (ClinicalTrials.gov)

Study Hypothesis: To estimate time to recurrence in pancreatic cancer patients treated with adjuvant erlotinib and gemcitabine. Combination therapy will be given for 4 months followed by single agent erlotinib for a total of 12 months.

Detailed description public domain (ClinicalTrials.gov)

PATIENT POPULATION Resected pancreatic cancer patients (R0 resection) within 10 weeks of surgery will be eligible, provided that they meet standard eligibility criteria. STUDY DESIGN Phase II, open-label trial of erlotinib and gemcitabine. SAFETY PLAN Safety as assessed by CTCAE 3.0 STUDY TREATMENT Erlotinib 150 mg/day x 12 months. (oral) Gemcitabine 1500 mg/m2 IV over 150 minutes q 2 weeks x 4 months Patients will be monitored with serial CT scans for the first 2 years after completion of therapy. Clinical Practice: Therapy will be administered as an outpatient. Primary Evaluations: Time to recurrence CONCOMITANT THERAPY AND CLINICAL PRACTICE No other anti-cancer therapy will be allowed while on study.

Intervention public domain (ClinicalTrials.gov)

Drug: Gemcitabine. 1500mg/m2 IV over 150 min IV q 2 weeks 4 months

Intervention public domain (ClinicalTrials.gov)

Drug: Erlotinib. 150 mg/d Daily, oral 12 months

Arm public domain (ClinicalTrials.gov)

Gemcitabine and Erlotinib (experimental): Erlotinib (oral) 150 mg/day x 12 months Gemcitabine 1500 mg/m2 IV over 150 minutes q 2 weeks x 4 months

Primary outcome public domain (ClinicalTrials.gov)

Recurrence Free Survival (RFS). The time interval between day 1, cycle 1, of adjuvant treatment to the first date of radiologic recurrence or death. Time frame: Up to 60 months.

Primary outcome public domain (ClinicalTrials.gov)

1-year Recurrence Free Survival (RFS). Time frame: Up to 60 months.

Primary outcome public domain (ClinicalTrials.gov)

2-year Recurrence Free Survival (RFS). Time frame: Up to 60 months.

Secondary outcome public domain (ClinicalTrials.gov)

Estimated 1&2 Year Overall Survival (OS). Time frame: Up to 60 months.

Secondary outcome public domain (ClinicalTrials.gov)

Percentage of Participants With Expression of Epidermal Growth Factor Receptor (EGFR). Time frame: Up to 60 months.

Secondary outcome public domain (ClinicalTrials.gov)

KRAS Mutational Status. Time frame: Up to 60 months.

Eligibility public domain (ClinicalTrials.gov)

Inclusion Criteria: * Patients with potentially resectable pancreatic cancer (including ampullary cancer), prior to or after surgery will be accrued to this study. * Patients who sign consent prior to surgery must have appropriate diagnostic imaging and be evaluated by one of the surgical co-investigators as having resectable disease, and probable pancreatic adenocarcinoma. * Patients, who sign consent after surgery, must have adenocarcinoma of the pancreas with negative surgical margins. * Adjuvant therapy should start within 10 weeks of surgery * Age 18 years or older * ECOG performance status of 0 - 1 (see Appendix A) * Ability to take oral medications without difficulty * Adequate bone marrow function as evidenced by an absolute neutrophil content (ANC) \> 1500/mL and platelet count \> 100,000/mL * Adequate renal function as evidenced by serum creatinine within institutional limits or creatinine clearance \> 50 ml/minute if above upper institutional limits (ULN) * Adequate hepatic function as evidenced by ALT and total bilirubin within 2 times ULN. * Provision of written informed consent. * Men and women of childbearing potential must be willing to practice acceptable methods of birth control to prevent pregnancy. Exclusion Criteria: * Positive margins on post operative surgical specimen or evidence of metastatic disease (positive retroperitoneal margin is allowed) * Biliary tree cancers are not allowed (Note: Ampullary cancer allowed). * Known severe hypersensitivity to erlotinib or any of the excipients of these products * Any prior treatment with radiation therapy or chemotherapy or vaccines for pancreatic cancer. * Other coexisting malignancies or malignancies diagnosed within the last 3 years, with the exception of basal cell carcinoma or squamous cell carcinoma of the skin or cervical cancer in situ. * Concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, phenobarbital, or St. John's Wort. Other agents which inhibit CYP3A4 may be used with caution (Appendix B) * Treatment with a non-approved or investigational drug prior to treatment. * Incomplete healing from previous oncologic or other major surgery. * Pregnancy or breast feeding (women of childbearing potential). * As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease). * Evidence of any other significant clinical disorder or laboratory finding that makes it …

Enrollment public domain (ClinicalTrials.gov)

Enrollment: 25 participants (actual).

Why stopped public domain (ClinicalTrials.gov)

Study published November 2010 and no further work will be done

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Recurrence Free Survival (RFS) [Up to 60 months]. Median, months (95% Confidence Interval). Gemcitabine (900-1500 mg/m^2) + Erlotinib (50-150 mg Daily) (n=25): 14 (8.2 to 24.5).

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

1-year Recurrence Free Survival (RFS) [Up to 60 months]. Number, percentage of participants (95% Confidence Interval). Gemcitabine (900-1500 mg/m^2) + Erlotinib (50-150 mg Daily) (n=25): 56 (35 to 73).

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

2-year Recurrence Free Survival (RFS) [Up to 60 months]. Number, percentage of participants (95% Confidence Interval). Gemcitabine (900-1500 mg/m^2) + Erlotinib (50-150 mg Daily) (n=25): 26 (6 to 52).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Estimated 1&2 Year Overall Survival (OS) [Up to 60 months]. Number, percentage of participants (95% Confidence Interval). Estimated 1-year OS: Gemcitabine (900-1500 mg/m^2) + Erlotinib (50-150 mg Daily) (n=25): 84 (63 to 94). Estimated 2-year OS: Gemcitabine (900-1500 mg/m^2) + Erlotinib (50-150 mg Daily) (n=25): 53 (22 to 76).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Percentage of Participants With Expression of Epidermal Growth Factor Receptor (EGFR) [Up to 60 months]. Number, percentage of participants. EGFR FISH - Negative: Gemcitabine (900-1500 mg/m^2) + Erlotinib (50-150 mg Daily) (n=25): 80. EGFR FISH - Positive: Gemcitabine (900-1500 mg/m^2) + Erlotinib (50-150 mg Daily) (n=25): 20. EGFR IHC - 1+ (incomplete circumferential): Gemcitabine (900-1500 mg/m^2) + Erlotinib (50-150 mg Daily) (n=25): 22. 2+ (complete circumferential): Gemcitabine (900-1500 mg/m^2) + Erlotinib (50-150 mg Daily) (n=25): 35. 3+ (complete strong circumferential): Gemcitabine (900-1500 mg/m^2) + Erlotinib (50-150 mg Daily) (n=25): 43.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

KRAS Mutational Status [Up to 60 months]. Number, percentage of participants. Gemcitabine (900-1500 mg/m^2) + Erlotinib (50-150 mg Daily) (n=25): 92.